Bas Koster

MSC.

20122019

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2019
2017

Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I–II melanoma: Data from two randomized phase II trials

Koster, B. D., Van Den Hout, M. F. C. M., Sluijter, B. J. R., Molenkamp, B. G., Vuylsteke, R. J. C. L. M., Baars, A., Van Leeuwen, P. A. M., Scheper, R. J., Petrousjka van den Tol, M., Van Den Eertwegh, A. J. M. & De Gruijl, T. D., 1 Oct 2017, In : Clinical Cancer Research. 23, 19, p. 5679-5686 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Melanoma sequentially suppresses different DC subsets in the sentinel lymph node, affecting disease spread and recurrence

Van Den Hout, M. F. C. M., Koster, B. D., Sluijter, B. J. R., Molenkamp, B. G., Van De Ven, R., Van Den Eertwegh, A. J. M., Scheper, R. J., Van Leeuwen, P. A. M., Van Den Tol, M. P. & De Gruijl, T. D., 1 Nov 2017, In : Cancer Immunology Research. 5, 11, p. 969-977 9 p.

Research output: Contribution to journalArticleAcademicpeer-review

Recent developments and future challenges in immune checkpoint inhibitory cancer treatment

Koster, B. D., de Gruijl, T. D. & van den Eertwegh, A. J. M., 2015, In : Current Opinion in Oncology. 27, 6, p. 482-488

Research output: Contribution to journalArticleAcademicpeer-review

2012

Response Breslow thickness and excision interval affect the activation state of Langerhans cells in melanoma sentinel lymph nodes

van den Hout, M. F. C. M., Koster, B. D., Sluijter, B. J. R., van Leeuwen, P. A. M., Meijer, S., van den Tol, M. P., van den Eertwegh, A. J. M., Scheper, R. J., van de Ven, R. & de Gruijl, T. D., 2012, In : Blood. 119, 20, p. 4809-4810

Research output: Contribution to journalArticleAcademicpeer-review